Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Machine learning applications in molecular oncology testing are largely in the research or early clinical implementation phase, though some ML methods have been part of bioinformatics tasks for years, such as variant effect prediction.
October 2024—For emergency physician Chadd Kraus, DO, DrPH, of Lehigh Valley Health Network, Allentown, Pa., caring for patients who may have sepsis often goes one of three ways.
October 2024—Instrument assessments for cyber safety are in need of a fast track—or another solution to the delays they’re creating, say some Compass Group laboratory leaders. They met online on Sept. 3 with CAP TODAY publisher Bob McGonnagle, with whom they also talked about mergers and acquisitions and Epic Beaker transitions.
October 2024—CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. The following report comes from Henry Ford Health. If you would like to submit a case report, please send an email to the AMP at amp@amp.org. For more information about the AMP and all previously published case reports, visit www.amp.org.
October 2024—In patients at risk for chronic kidney disease, clinical practice guidelines released this year recommend the combined creatinine and cystatin C-based estimated glomerular filtration rate over the creatinine-based eGFR when cystatin C is available. “Cystatin C isn’t perfect itself, but a combination of the two seems to hit the sweet spot,” Angela Ferguson, PhD, D(ABCC), said in a session at the ADLM meeting in July. Dr. Ferguson is associate professor at the University of Missouri-Kansas City School of Medicine and co-director of clinical chemistry, director of immunology, and director of point-of-care testing in the Department of Pathology and Laboratory Medicine, Children’s Mercy Kansas City. The guidelines were released by the Kidney Disease: Improving Global Outcomes chronic kidney disease work group.
October 2024—Do clinicians understand how the technology in hematology has evolved and how laboratory data can help guide their decisions? It’s a question roundtable participants took on when they met online Aug. 29 with CAP TODAY publisher Bob McGonnagle. “There’s a disconnect with our clinical colleagues,” said Olga Pozdnyakova, MD, PhD, of the Hospital of the University of Pennsylvania. She and others spoke about solutions, instruments, AI, and reference ranges—in addition to the staffing shortage. “It is first and foremost in our minds,” Maria (Ria) Vergara-Lluri, MD, of Keck School of Medicine of USC, said of the ongoing shortage.
September 2024—Every profession has its own news cycle. In pathology, the story arc is often a lengthy one, stretching from clinical triumph to Now what? Such is the case with expanded use of trastuzumab deruxtecan, which was granted accelerated FDA approval in late April for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received prior systemic treatment and have no alternative treatment options. Three multicenter trials evaluated the efficacy of the drug: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. PanTumor02 looked at seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other solid cancers (excluding breast, colorectal, gastric, and non-small cell lung cancers). The results of these trials often were striking (median duration of response for PanTumor02 was 19.4 months, for example), and physicians are now looking closely at this tumor-agnostic (also referred to as tissue-agnostic) indication.
September 2024—Leomar Ballester, MD, PhD, of the University of Texas MD Anderson Cancer Center has simple advice for those called to provide an intraoperative neuropathologic consultation: review the imaging and know the entities.
September 2024—In HPV primary screening, self-collected vaginal samples enable accurate clinical HPV testing, and neither extended ambient dry storage nor exposure to extreme temperatures influence HPV detection, say the authors of a study published in June.
September 2024—When emergency physician Chadd Kraus, DO, DrPH, of Lehigh Valley Health Network in Allentown, Pa., sees a patient who could have sepsis, he wants to know if there’s an infection and, if so, how bad it is based on the patient’s host response, what interventions are needed, and whether the patient will need to be hospitalized.
